Suchergebnisse - "Kim, Kye-Hyung"

PubPharm (6)

1

Regdanvimab in patients with mild-to-moderate SARS-CoV-2 infection : A propensity score-matched retrospective cohort study

enthalten in: International immunopharmacology | 2022

von Lee, S. | Lee, S. | Lee, J. | +9

2

Persistence of Neutralizing Antibody Response up to 1 Year After Asymptomatic or Symptomatic SARS-CoV-2 Infection

enthalten in: The Journal of infectious diseases | 2021

von Choe, P. | Kang, C. | Kim, K. | +6

CommentOn: J Infect Dis. 2021 Aug 16;224(4):586-594. - PMID 33978754

3

Antibody Responses One Year after Mild SARS-CoV-2 Infection

enthalten in: Journal of Korean medical science | 2021

von Choe, P. | Kim, K. | Kang, C. | +7

4

Antibody Responses 8 Months after Asymptomatic or Mild SARS-CoV-2 Infection

enthalten in: Emerging infectious diseases | 2021

von Choe, P. | Kim, K. | Kang, C. | +7

5

Comparative outcomes of lopinavir/ritonavir and hydroxychloroquine for the treatment of COVID-19 with mild-to-moderate severity : A retrospective observational study

enthalten in: Antiviral therapy | 2021

von Lee, J. | Lee, S. | Heo, J. | +7

6

Comparative outcomes of lopinavir/ritonavir and hydroxychloroquine for the treatment of coronavirus disease 2019 with mild to moderate severity.

enthalten in: ResearchSquare.com | 2020

von Lee, J. | Lee, S. | Heo, J. | +7

1
[1]